LUND, SWEDEN – Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm: CANTA) today reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). This trial is financed through a grant from the US Department of...
Latest News
LUND, Sweden – Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm:CANTA) today reported that after both FDA and IRB review, regulatory approval has been granted to start recruiting patients in a controlled phase IIb trial in metastatic pancreatic cancer (PDAC) investigating nadunolimab as first line combination therapy. The trial is planned to...
Standing up sends pain through Trevor Wiberg’s back, and lifting a box is enough to throw his arm out of joint. Yet, many who meet him, including medical professionals, take one look at him and assume he’s a drug addict. His medical condition is so painful he relies on narcotics...
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the...
San Diego — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced that the Company presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002,...
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of...
THOUSAND OAKS, Calif. — Capsida Biotherapeutics today announced new preclinical data supporting the potential of Capsida’s gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations. Gene therapy for genetic epilepsy due to STXBP1...
San Francisco, California – Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology. A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being...
HOUSTON, Texas – Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer. The therapy...
Among patients with refractory large B cell lymphoma (LBCL), chimeric antigen receptor (CAR)-T cell therapy appears to yield superior long-term clinical outcomes to those seen with standard salvage therapy regimens, according to an analysis published in Blood Advances. Treatments for LBCL, the most common non-Hodgkin lymphoma subtype, have improved over the...